Cargando…

Suppression of OCT-1 in Metastatic Breast Cancer Cells Reduces Tumor Metastatic Potential, Hypoxia Resistance, and Drug Resistance

OCT-1/POU2F1 is a ubiquitously expressed transcription factor. Its expression starts at the earliest stage of embryonic development. OCT-1 controls genes involved in the regulation of differentiation, proliferation, cell metabolism, and aging. High levels of OCT-1 transcription factor in tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stepchenko, Alexander G., Bulavkina, Elizaveta V., Portseva, Tatiana N., Georgieva, Sofia G., Pankratova, Elizaveta V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502003/ https://www.ncbi.nlm.nih.gov/pubmed/36143471 http://dx.doi.org/10.3390/life12091435

Ejemplares similares

The regulatory interplay between Oct-1 isoforms contributes to hematopoiesis and the isoforms imbalance correlates with a malignant transformation of B cells
por: Pankratova, Elizaveta V., et al.
Publicado: (2018)

Different N-terminal isoforms of Oct-1 control expression of distinct sets of genes and their high levels in Namalwa Burkitt's lymphoma cells affect a wide range of cellular processes
por: Pankratova, Elizaveta V., et al.
Publicado: (2016)

Primate-specific stress-induced transcription factor POU2F1Z protects human neuronal cells from stress
por: Stepchenko, Alexander G., et al.
Publicado: (2021)

GSK3 Kinase Inhibitor, CHIR, Suppress Transcription of Tissue Specific POU2F1 Isoform in Burkitt Namalwa Lymphoma Cells
por: Pankratova, E. V., et al.
Publicado: (2021)

5-Azacytidine Suppresses the Expression of Tissue-Specific Oct-1 Isoform in Namalwa Burkitt’s Lymphoma Cell Culture
por: Kotnova, A. P., et al.
Publicado: (2022)

The alternative protein isoform NK2B, encoded by the vnd/NK-2 proneural gene, directly activates transcription and is expressed following the start of cells differentiation
por: Stepchenko, Alexander G., et al.
Publicado: (2011)

Triple-negative and triple-positive breast cancer cells reciprocally control their growth and migration via the S100A4 pathway
por: Dukhanina, Elena A., et al.
Publicado: (2022)

The Emergence of a New Isoform of POU2F1 in Primates through the Use of Egoistic Mobile Genetic Elements
por: Lyanova, B. M., et al.
Publicado: (2022)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients
por: Abdelaziz, Lobna A., et al.
Publicado: (2022)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939
por: Pudova, Elena, et al.
Publicado: (2022)

Penetrating cations induce pleiotropic drug resistance in yeast
por: Galkina, Kseniia V., et al.
Publicado: (2018)

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue
por: Gote, Vrinda, et al.
Publicado: (2021)

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022)

Tyrosol induces multiple drug resistance in yeast Saccharomyces cerevisiae
por: Noskova, Elizaveta O., et al.
Publicado: (2023)

Proteomic Markers for Mechanobiological Properties of Metastatic Cancer Cells
por: Leonov, Sergey, et al.
Publicado: (2023)

Encapsulation and adhesion of nanoparticles as a potential biomarker for TNBC cells metastatic propensity
por: Merkher, Yulia, et al.
Publicado: (2023)

Jadomycins: A potential chemotherapy for multi‐drug resistant metastatic breast cancer
por: Bonitto, Esther P., et al.
Publicado: (2021)

HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer
por: Raju, Ganji Seeta Rama, et al.
Publicado: (2023)

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates
por: Heater, Natalie K., et al.
Publicado: (2023)

The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia
por: Bhatavdekar, Omkar, et al.
Publicado: (2022)

Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance.
por: Sakata, K., et al.
Publicado: (1991)

SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
por: Chen, Hao, et al.
Publicado: (2020)

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
por: Reni, M, et al.
Publicado: (2006)

Penfluridol overcomes paclitaxel resistance in metastatic breast cancer
por: Gupta, Nehal, et al.
Publicado: (2019)

Relationship of hypoxia to metastatic ability in rodent tumours
por: Jaeger, K De, et al.
Publicado: (2001)

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Upregulation of the Oct3/4 Network in Basal Breast Cancer Is Associated with Its Metastatic Potential and Shows Tissue Dependent Variability
por: Rajan, Robin G., et al.
Publicado: (2023)

HDAC Inhibition Impedes Epithelial-Mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer
por: Ruscetti, Marcus, et al.
Publicado: (2015)

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
por: Kim, Kibem, et al.
Publicado: (2014)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy
por: Wong, Adriana J., et al.
Publicado: (2022)

Tumor hypoxia drives immune suppression and immunotherapy resistance
por: Ai, Midan, et al.
Publicado: (2015)

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
por: Rivera, Edgardo, et al.
Publicado: (2010)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells
por: Gonçalves da Silva, Patrícia Benites, et al.
Publicado: (2017)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
por: Sceneay, Jaclyn, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c3ee6ctuej5ttuk5bmr8soceiu